"Abstral will be a disaster BECAUSE OF Fentora's success. The market is going generic. Too many options. Actiq, Fentora, Onsolis, Abstral, Subsys, Lazanda. And that's just the fentanyls. Think about all the docs managing breakthrough pain with the generic immediate-release opioids. Only pain specialists prescribe this stuff, and there are only so many of them. Too many sailors on the lifeboat. Things are leaky."
LOL -- most ridiculous post I've read in a long time.
Pain management is very, very needed beyond the opiod realm. Trust me. This I know. Easy, effective and quick is the name of the game. Abstral is all that -- way better than the Insys product.
Let results of sales speak for themselves. Not much longer to wait!
Sentiment: Strong Buy